Price Alert: Shares of Forma (FMTX) Trade 9.32% Higher at Midday June 21

Equities Staff  |

Shares of Forma Therapeutics Holdings Inc (NASDAQ: FMTX) are up 9.32% Tuesday.

As of 11:53:56 est, Forma sits at $6.19 and has moved $0.53 so far today.

Forma has moved 5.17% over the last 30 days and has moved YTD 59.99% based on the most recent close.

The company anticipates its next earnings on 2022-08-09.

For technical charts, analysis, and more on Forma visit the company profile.

About Forma Therapeutics Holdings Inc

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Its R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Its work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

To get more information on Forma Therapeutics Holdings Inc and to follow the company's latest updates, you can visit the company's profile page here: Forma Therapeutics Holdings Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content